These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 18094420)

  • 21. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
    Lee KM; Cao D; Itami A; Pour PM; Hruban RH; Maitra A; Ouellette MM
    Histopathology; 2007 Oct; 51(4):539-46. PubMed ID: 17714470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.
    Wilentz RE; Iacobuzio-Donahue CA; Argani P; McCarthy DM; Parsons JL; Yeo CJ; Kern SE; Hruban RH
    Cancer Res; 2000 Apr; 60(7):2002-6. PubMed ID: 10766191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).
    Hermanová M; Lukás Z; Nenutil R; Brázdil J; Kroupová I; Kren L; Pazourková M; Růzicka M; Díte P
    Neoplasma; 2004; 51(2):77-83. PubMed ID: 15190415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytologic features of pancreatic intraepithelial neoplasia and pancreatitis: potential pitfalls in the diagnosis of pancreatic ductal carcinoma.
    Jarboe EA; Layfield LJ
    Diagn Cytopathol; 2011 Aug; 39(8):575-81. PubMed ID: 20730891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S100P is an early developmental marker of pancreatic carcinogenesis.
    Ohuchida K; Mizumoto K; Egami T; Yamaguchi H; Fujii K; Konomi H; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
    Clin Cancer Res; 2006 Sep; 12(18):5411-6. PubMed ID: 17000674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucin expression profile in pancreatic cancer and the precursor lesions.
    Nagata K; Horinouchi M; Saitou M; Higashi M; Nomoto M; Goto M; Yonezawa S
    J Hepatobiliary Pancreat Surg; 2007; 14(3):243-54. PubMed ID: 17520199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis.
    Ohuchida K; Mizumoto K; Miyasaka Y; Yu J; Cui L; Yamaguchi H; Toma H; Takahata S; Sato N; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
    J Pathol; 2007 Nov; 213(3):275-82. PubMed ID: 17940995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression.
    Klein WM; Hruban RH; Klein-Szanto AJ; Wilentz RE
    Mod Pathol; 2002 Apr; 15(4):441-7. PubMed ID: 11950919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach.
    Katabi N; Klimstra DS
    J Clin Pathol; 2008 Dec; 61(12):1303-13. PubMed ID: 18703569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased expression of MUC1 in advanced pancreatic cancer.
    Hinoda Y; Ikematsu Y; Horinochi M; Sato S; Yamamoto K; Nakano T; Fukui M; Suehiro Y; Hamanaka Y; Nishikawa Y; Kida H; Waki S; Oka M; Imai K; Yonezawa S
    J Gastroenterol; 2003; 38(12):1162-6. PubMed ID: 14714254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MUC gene family: their role in diagnosis and early detection of pancreatic cancer.
    Ringel J; Löhr M
    Mol Cancer; 2003 Jan; 2():9. PubMed ID: 12556240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic intraepithelial neoplasia revisited and updated.
    Sipos B; Frank S; Gress T; Hahn S; Klöppel G
    Pancreatology; 2009; 9(1-2):45-54. PubMed ID: 19077454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling.
    McCarthy DM; Brat DJ; Wilentz RE; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Hum Pathol; 2001 Jun; 32(6):638-42. PubMed ID: 11431719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Precursors to pancreatic cancer].
    Søreide K; Immervoll H; Molven A
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):905-8. PubMed ID: 16554881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of MUC apomucins in normal pancreas and pancreatic tumours.
    Terada T; Ohta T; Sasaki M; Nakanuma Y; Kim YS
    J Pathol; 1996 Oct; 180(2):160-5. PubMed ID: 8976874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of pancreatic intraepithelial neoplasia and mucin expression in normal pancreata.
    Matsuyama M; Kondo F; Ishihara T; Yamaguchi T; Ito R; Tsuyuguchi T; Tawada K; Yokosuka O
    J Hepatobiliary Pancreat Sci; 2012 May; 19(3):242-8. PubMed ID: 21644061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
    Burke PA; Gregg JP; Bakhtiar B; Beckett LA; Denardo GL; Albrecht H; De Vere White RW; De Nardo SJ
    Int J Oncol; 2006 Jul; 29(1):49-55. PubMed ID: 16773184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
    Gold DV; Newsome G; Liu D; Goldenberg DM
    Mol Cancer; 2013 Nov; 12(1):143. PubMed ID: 24257318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation.
    Sitek B; Sipos B; Alkatout I; Poschmann G; Stephan C; Schulenborg T; Marcus K; Lüttges J; Dittert DD; Baretton G; Schmiegel W; Hahn SA; Klöppel G; Meyer HE; Stühler K
    J Proteome Res; 2009 Apr; 8(4):1647-56. PubMed ID: 19714807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.